You Can Do Better Than SpaceX: 2 Industrial Stocks to Buy Instead

Rocket Lab has secured a U.S. national-security satellite contract worth up to $397 million and agreed in June to acquire Iridium for about $8 billion, but its Neutron debut has been pushed to 2027 amid technical challenges. The article cites Rocket Lab at about 44x sales and Redwire at just under 4x, while noting Rocket Lab’s development and competition risks and Redwire’s contract-timing, manufacturing, and acquisition-integration risks. It presents Rocket Lab as the more cautious growth option and Redwire as the higher-risk, lower-valuation alternative.

Analysis

The key underwriting issue is not the headline contract ceiling; it is whether Rocket Lab can convert awards into funded backlog and cash flow while simultaneously taking on a radically different business. An “up to” award is not equivalent to revenue, and the reported roughly $8B Iridium transaction would materially change RKLB’s capital needs, leverage, integration burden, and exposure from manufacturing into satellite operations. Verify the definitive agreement, financing mix, closing conditions, and regulatory approvals before treating the acquisition as a catalyst. If confirmed on the stated scale, dilution or debt risk could overwhelm near-term launch and defense wins.

For RKLB, Neutron’s 2027 timing makes the next several quarters a credibility test: further slips could compress a valuation that leaves little execution cushion, while a successful test cadence and funded national-security backlog would support the longer-term case. Independent launch providers could benefit if SpaceX capacity is constrained by internal missions, but that is conditional—not a bankable demand forecast.

RDW’s lower sales multiple is not by itself a margin of safety. Contract timing, manufacturing execution, and acquisition integration can make reported sales a poor proxy for durable cash generation. Defense demand may diversify exposure, but investors should look for funded awards, conversion to revenue, and improving cash economics rather than citing demand commentary alone. The contrarian risk is that investors anchor on the relative P/S gap without adjusting for business mix, growth, dilution, and cash conversion. Near term, the article supports verification and monitoring, not an automatic sector trade.

Key Decisions for Investors

• RKLB: Do not add on the acquisition headline alone. First verify the Iridium agreement and obtain purchase consideration, financing sources, pro forma leverage/dilution, closing conditions, and expected cash contribution; reassess only when these are disclosed.
• RKLB watch: Treat Neutron schedule and funded backlog as the 1–3 month execution tests. Further schedule slippage or weak cash conversion would falsify the bullish execution case; credible milestone progress and funded awards would improve it.
• RDW: Keep on a watchlist rather than buying solely on the lower P/S. Track quarterly funded backlog, revenue conversion, cash flow, and acquisition-related costs; deterioration in conversion or integration metrics would invalidate the cheap-versus-RKLB framing.
• No forced pair trade: RKLB and RDW have materially different business and event risks. Revisit relative value after verifying RKLB deal terms and comparing forward sales quality and cash conversion; until then, a short RKLB/long RDW spread has significant deal and execution basis risk.